Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1B | P36896 | 1/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 6/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.48 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340908 | 0.84 | HRH4 (0.44) | ACVR1BTGFBR1TLR9TLR8TLR7 | |
| SCHEMBL15344115 | 0.84 | ACVR1B (0.57) | ACVR1BTGFBR1FYNTLR9TLR8 | |
| SCHEMBL15340948 | 0.81 | ATM (0.53) | FYNTLR9TLR8TLR7TNKS | |
| SCHEMBL10203431 | 0.79 | HRH4 (0.56) | TLR9TLR8TLR7HRH4 | |
| SCHEMBL13086694 | 0.78 | TLR9 (0.48) | FYNTLR9TLR8TLR7TNKS | |
| SCHEMBL10127337 | 0.77 | HTR3A (0.49) | HRH4 | |
| SCHEMBL13086691 | 0.76 | TDO2 (0.48) | FYNTLR9TLR8TLR7TNKS | |
| SCHEMBL13086695 | 0.75 | RET (0.48) | FYNTLR9TLR8TLR7TNKS | |
| SCHEMBL13086456 | 0.74 | FYN (0.46) | FYNTLR9TLR8TLR7ZAP70 | |
| SCHEMBL29883568 | 0.74 | HRH4 (0.62) | ACVR1BTGFBR1FYNZAP70TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ACVR1B 4089/4885TGFBR1 4545/4885FYN 823/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | ACVR1B 568/4885TGFBR1 4701/4885FYN 2654/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ACVR1B 4089/4885TGFBR1 4545/4885FYN 823/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ACVR1B 4089/4885TGFBR1 4545/4885FYN 823/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | ACVR1B 568/4885TGFBR1 4701/4885FYN 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.